Ficlatuzumab inhibited HNSCC cell growth mediated by tumor-associated fibroblast (TAF)-secreted HGF by blocking vimentin expression induced by conditioned medium derived from TAFs. This evidence concerns the gene HGF and head and neck squamous cell carcinoma.